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TaiwanAbstract In Taiwan, the number of new cases of human immunodeficiency virus (HIV) infec-
tion via drug injection has been increasing since 2003. Due to HIV and hepatitis B virus (HBV)
having similar transmission routes, HBV and HIV infections among injecting drug users (IDUs)
has become an important public health issue. The aim of this study was explore the prevalence
of HBV infection among IDUs with and without HIV infection, and examine whether HIV infec-
tion is associated with HBV infection among IDUs in Southern Taiwan. We enrolled 566 IDUs,
including 87 anti-HBV positive IDUs and 479 anti-HBV negative IDUs, and also analyzed the re-
sults of liver function tests, HBV DNA, anti-HIV, HIV RNA, and CD4 cell count. The results
showed that the prevalence of HBV infection among IDUs was 15.4%. The prevalence of hepa-
titis B surface antigen (HBsAg) was higher among individuals born before 1985 (15.9% vs. 4.0%),
but this was not significant. Anti-HIV seropositivity was related to HBsAg seropositivity [odds
ratio (OR) Z 2.47, 95% confidence interval Z 1.26e4.82, p Z 0.008). Anti-HCV and anti-HIV
were risk factors for abnormal alanine aminotransferase (ALT; OR Z 2.11, 95% confidence
interval Z 1.005e4.42, p Z 0.048 and OR Z 1.47, 95% confidence interval Z 1.02e2.10,
p Z 0.04, respectively), and HBsAg was not a factor related to abnormal ALT. In conclusion,
the prevalence of HBV infection was similar in the general population and in IDUs, and due
to anti-HIV seropositivity being significantly related to HBsAg seropositivity, HBV infection
among IDUs is still important. We suggest that for IDUs, HBsAg should be monitored closely.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
The hepatitis B virus (HBV) and the human immunodefi-
ciency virus (HIV) are global viral infectious diseases. Pre-
vious studies have reported that persons with chronic HBV
infection number approximately 240 million [1] and HIV
infections total approximately 36.9 million [2], and there
may be 3 to 6 million HIV-infected people coinfected with
chronic HBV [3]. These two viruses contribute to deaths
from diseases worldwide [4], and are viewed as important
public health issues in Taiwan. Before 1984, vertical
transmission of HBV was the main reason for the high
prevalence of hepatitis B surface antigen (HBsAg) seropos-
itivity; therefore effecting a decrease in the vertical
transmission of HBV is important in order to reduce the
spread of HBV infection. After a mass vaccination program
against HBV infection was initiated in 1984, the prevalence
gradually decreased [5].
HBV and HIV share common routes of transmission,
especially blood-borne transmission, such as injecting drug
use, etc. [6]. Injecting drug use is a very important cause of
HBV infection worldwide [7]. A previous study reported that
injecting drug users (IDUs) have higher prevalences of HBV
and HIV infections than non-IDUs [8], and so the risk of
coinfection with HBV and HIV is higher in IDUs.
In Taiwan, new cases of HIV infection via injecting drug
use have been increasing since 2003, and this transmission
route has been one of the most important routes of trans-
mission of HIV since 2005 [9]. Regarding HBV, 40e50% of
chronic hepatitis B (CHB) cases are due to perinatal
mother-to-infant transmission, and the remainder is due to
horizontal transmission [10,11]. Taiwan is an area of high
prevalence of HBsAg, the prevalence of HBsAg in the gen-
eral population being 15e20% [12]. In addition, HBsAg is
detected in 5e15% of HIV-infected persons globally [13].Previous studies have mentioned that HIV infection is
associated with failure to seroconvert following acute
infection and a greater risk of developing chronic hepatitis
B infection as compared with HIV seronegative persons
[14e16]. Among HIV-infected persons with chronic HBV
infection (e.g., persistent detection of HBsAg), progressive
liver fibrosis, cirrhosis, end stage liver disease (ESLD) and
hepatocellular carcinoma (HCC) can occur [17e19]. Simi-
larly, HBV negatively impacting on HIV outcomes was also
reported [20]. Because HBV and HIV coinfection is an
important public health issue, especially among IDUs, the
aim of this study was to explore the prevalence of HBV
infection among IDUs, and examine whether HIV infection is
associated with HBV infection among IDUs in Taiwan.Materials and methods
Participants
We enrolled IDUs from three prisons and Kaohsiung Medical
University Chung-Ho Memorial Hospital from March 2008 to
June 2010. We excluded persons with severe liver, renal, or
other systemic disease, such as decompensated hepatic
failure, renal failure, any malignant disease, or severe
heart failure, etc. Finally, we enrolled 566 IDUs, including
479 anti-HBV negative IDUs and 87 anti-HBV positive IDUs.
The study was approved by the ethics committee of Kaoh-
siung Medical University Hospital. Signed informed consent
was obtained from all participants.
Laboratory data
We measured the levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), HBsAg, HBV DNA,
98 M.-H. Hsieh et al.anti-HIV antibody, HIV RNA viral load, CD4 cell count and
anti-hepatitis C virus (HCV) antibody. HBsAg was examined
by enzyme immunoassay (EIA; Abbott Laboratories, North
Chicago, IL, USA), and quantitative HBV DNA was performed
by the Roche Cobas Apliprep/Cobas Taqman HBV Test
(Roche Molecular System, Roche, Branchburg, USA). Anti-
HCV antibody was detected using a third-generation,
commercially-available enzyme-linked immunosorbent
assay kit (AxSYM 3.0; Abbott Laboratories, Chicago, IL,
USA). Anti-HIV antibody assay (SERODIA-HIV; Fujirebio,
Tokyo, Japan) was performed as per the manufacturer’s
instructions. HIV viral loads were quantified using an RT-
PCR assay (COBAS Amplicor, version 1.5; Roche Diagnostics,
Branchburg, NJ, USA), and CD4 counts were determined
using a flow cytometer (BD FACSCalibur; Becton Dickinson,
San Jose, CA, USA).
Statistical analysis
The statistical tests employed in this study were Student t-
test, the c2 test, the Mann-Whitney U test, and one-way
ANOVA. In addition, multivariate analysis was used forTable 1 Basic characteristics of the participants included
in this study.
Item Value
Total, n (%) 566 (100.0)
Age (y) 36.2  7.5
Born before 1985, n (%) 541 (95.6)
Born after 1985, n (%) 25 (4.4)
Sex
Male, n (%) 406 (71.7)
Female, n (%) 160 (28.3)
AST (ratio for UNL) 0.95  0.68
ALT (ratio for UNL) 1.18  1.19
Anti-HIV
Negative, n (%) 265 (48.6)
Positive, n (%) 301 (53.2)
HIV RNA [log(IU/ml)]b 3.16  0.88
HBsAg
Negative, n (%) 479 (84.6)
Positive, n (%) 87 (15.4)
Anti-HCV
Negative, n (%) 49 (8.7)
Positive, n (%) 517 (91.3)
HCV RNAa
Undetectable, n (%) 100 (19.5)
Detectable, n (%) 412 (80.5)
CD4 cell countb 443.4  180.4
> 500 cells/mL 95 (31.6)
< 500 cells/mL 206 (68.4)
Among hepatitis B surface antigen seropositive participants, the
prevalence of hepatitis B virus DNA detectable was 56.3%.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; HBsAg Z hepatitis B surface antigen;
HCVZ hepatitis C virus; HIVZ human immunodeficiency virus;
UNL Z upper normal limit.
a For 512 hepatitis C virus RNA detectable individuals.
b For 301 injecting drug users with human immunodeficiency
virus infection.estimating the odds ratios (ORs) and 95% confidence in-
tervals. All of these tests were two-sided, and the signifi-
cance levels were set at a Z 0.05. The procedures were
performed using the SPSS 19th edition statistical package
(SPSS Inc., Chicago, IL, USA).Results
In this study, 566 IDUs were enrolled. Males were dominant
(71.7%), and most of the participants in this study were
born before 1985 (95.6%). The prevalences of HBsAg sero-
positivity, anti-HIV, and anti-HCV were 15.4%, 53.2% and
91.3%, respectively (Table 1). In addition, the prevalences
of HBsAg among IDUs without and with HIV infection were
11.3% (30/265) and 18.9% (57/301), respectively, and sig-
nificant difference was also noted (p Z 0.01; not shown in
the table).
Table 2 shows the data for IDUs born before and after
1985. Sex, HIV RNA level, anti-HCV, and whether HCV RNA
was detectable or not differed significantly between these
two groups. Even though HBsAg did not differ significantlyTable 2 Characteristics of injecting drug users (IDUs) born
before and after 1985.
Univariate analysis
Born before
1985
Born after
1985
p
Total, n (%) 541 (95.6) 25 (4.4)
Age (y) 36.7  7.1 23.9  1.6 < 0.001
Sex
Male, n (%) 395 (73.0) 11 (44.0) 0.002
Female, n (%) 146 (27.0) 14 (56.0)
AST (ratio for UNL) 0.94  0.67 0.97  0.82 0.88
ALT (ratio for UNL) 1.17  1.31 1.16  1.77 0.38a
Anti-HIV
Negative, n (%) 249 (46.0) 16 (64.0) 0.08
Positive, n (%) 292 (54.0) 9 (36.0)
HIV RNA
[log(IU/ml)]
4.48  1.77 3.40  1.92 0.005
HBsAg
Negative, n (%) 455 (84.1) 24 (96.0) 0.11
Positive, n (%) 86 (15.9) 1 (4.0)
Anti-HCV
Negative, n (%) 44 (8.1) 5 (20.0) 0.04
Positive, n (%) 497 (91.9) 20 (80.0)
HCV RNA
Undetectable,
n (%)
91 (18.6) 9 (40.9) 0.01
Detectable, n (%) 399 (81.4) 13 (59.1)
CD4 cell countb 441.1  178.5 519.1  233.7 0.20
> 500 cells/mL 91 (31.2) 4 (44.4) 0.40
< 500 cells/mL 201 (68.8) 5 (55.6)
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; HBsAg Z hepatitis B surface antigen;
HCVZ hepatitis C virus; HIVZ human immunodeficiency virus;
UNL Z upper normal limit.
a ManneWhitney U test.
b For 301 IDUs with human immunodeficiency virus infection.
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higher among individuals born before 1985 (15.9% vs. 4.0%,
p Z 0.11).
Table 3 shows the associations of HBsAg seropositivity
among IDUs who were born before 1985. Univariate analysis
showed that anti-HIV antibody and HCV RNA were related to
HBsAg (p < 0.05). According to multivariate analysis, anti-
HIV seropositivity was related to HBsAg seropositivity
(OR Z 2.47, 95% confidence interval Z 1.26e4.82,
p Z 0.008), and anti-HCV seronegativity was related to
HBsAg seropositivity (OR Z 0.22, 95% confidence
interval Z 0.11e0.45, p < 0.001). The prevalence of anti-
HIV seropositivity was higher among the HBsAg seroposi-
tive participants than the HBsAg seronegative participants
(65.1% vs. 5019%, p Z 0.02).
Table 4 analyzes the factors associated with HBV DNA
being detectable and undetectable among HBsAg-positive
IDUs. From Table 4, only the CD4 cell count was related
to HBV DNA in univariate analysis, but the CD4 cell count
was higher among HBV DNA- undetectable individuals. No
item was related to HBV DNA according to multivariate
analysis. In addition, for 31 HBsAg-positive IDUs with hep-
atitis B e antigen (HBeAg) data available, HBeAg was not
significantly different between HBV DNA-undetectable and
-detectable individuals (0.0% vs. 10.0%, p Z 0.14, not
shown in table). Unlike HBsAg, the prevalence of anti-HIVTable 3 Factors associated with hepatitis B surface antigen sero
Univariate analysis
HBsAg negative HBsAg positive p
Total, n (%) 455 (84.1) 86 (15.9)
Age (y) 36.9  7.2 35.6  6.7 0.
Sex
Male, n (%) 328 (72.1) 67 (77.9) 0.
Female, n (%) 127 (27.9) 19 (22.1)
AST (ratio for UNL) 0.94  0.70 0.94  0.52 0.
ALT (ratio for UNL) 1.17  1.20 1.17  0.89 0.
Anti-HIV
Negative, n (%) 219 (48.1) 30 (34.9) 0.
Positive, n (%) 236 (51.9) 55 (65.1)
HIV RNA [log(IU/ml)]b,c 4.57  1.70 3.95  2.03 0.
Anti-HCV
Negative, n (%) 36 (7.9) 8 (9.3) 0.
Positive, n (%) 419 (92.1) 78 (90.7)
HCV RNA
Undetectable, n (%) 68 (16.1) 23 (34.3) < 0.
Detectable, n (%) 355 (83.9) 44 (65.7)
CD4 cell countd 439.9  183.6 446.2  156.5 0.
> 500 cells/mL 70 (29.7) 21 (37.5) 0.
< 500 cells/mL 166 (70.3) 35 (62.5)
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
HCV Z hepatitis C virus; HIV Z human immunodeficiency virus; UNL
a Factors used for logistic analysis included sex, aspartate aminotr
RNA detectable or undetectable, and anti-human immunodeficiency
b ManneWhitney U test.
c Mean  standard deviation.
d For 301 IDUs with HIV infection.seropositivity was higher among HBV DNA-undetectable
than HBV DNA-detectable individuals (68.4% vs. 63.3%,
p Z 0.62).
This study showed that ALTwas associated with anti-HCV
and anti-HIV levels. According to the results of univariate
analysis, anti-HCV and anti-HIV were significantly different
between patients with ALT within the upper normal limit
(UNL) and those with ALT greater than UNL, and multivar-
iate analysis showed that anti-HCV and anti-HIV were risk
factors for abnormal ALT (OR Z 2.11, 95% confidence
interval Z 1.005e4.42, p Z 0.048 and OR Z 1.47, 95%
confidence interval Z 1.02e2.10, p Z 0.04, respectively;
Table 5).
Discussion
Previous studies have reported that Taiwan is an area of
high prevalence of HBV and HCV infection, the prevalence
of HBsAg seropositivity being 15.1% and that of anti-HCV
seropositivity being 8.6% [21]. One study from Luxembourg
reported that the prevalences of HBV and HCV seroposi-
tivity among IDUs are 24.7% (59/239) and 81.3% (218/268),
respectively [22], and another study from Dali, China, re-
ported that the prevalences of HBV and HCV seropositivity
among IDUs are 72.0% (296/411) and 90.8% (452/498),
respectively [23]. In this study, the prevalence of HBsAgpositivity among injecting drug users (IDUs) born before 1985.
Multivariate analysisa
Comparison Odds ratio 95% CI p
11
27
97
17b
02 Negative Z 0,
positive Z 1
2.47 1.26e4.82 0.008
08
66
001 Undetectable Z 0,
detectable Z 1
0.22 0.11e0.45 < 0.001
81
26
CI Z confidence interval; HBsAg Z hepatitis B surface antigen;
Z upper normal limit.
ansferase ratio, alanine aminotransferase ratio, hepatitis C virus
virus (HIV) status.
Table 4 Factors associated with hepatitis B virus DNA-
detectable and -undetectable among hepatitis B surface
antigen (HBsAg)-positive injecting drug users (IDUs).
HBV DNA-
undetectable
HBV DNA-
detectable
p
Total, n (%) 38 (43.7) 49 (56.3)
Age (y) 36.0  6.0 35.1  7.4 0.53
Sex
Male, n (%) 32 (84.2) 36 (73.5) 0.23
Female, n (%) 6 (15.8) 13 (26.5)
AST (ratio for UNL) 0.98  0.54 0.90  0.49 0.47
ALT (ratio for UNL) 1.22  0.87 1.13  0.91 0.66
Anti-HIV
Negative, n (%) 12 (31.6) 18 (36.7) 0.62
Positive, n (%) 26 (68.4) 31 (63.3)
Anti-HCV
Negative, n (%) 4 (10.5) 4 (2.2) 0.71
Positive, n (%) 34 (89.5) 45 (91.8)
HCV RNAa
Undetectable,
n (%)
9 (28.1) 15 (47.1) 0.24
Detectable, n (%) 23 (71.9) 21 (58.3)
HIV RNA
[log(IU/ml)]b
3.07  0.88 3.28  0.56 0.28
CD4 cell countb 497.2.4  161.2 406.2  139.9 0.03
>500 cells/mL 12 (46.2) 10 (32.3) 0.28
<500 cells/mL 14 (53.8) 21 (67.7)
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; HBV Z hepatitis B virus; HCV Z hepatitis C virus;
HIV Z human immunodeficiency virus; UNL Z upper normal
limit.
a For 68 HBsAg-positive IDUs with hepatitis C virus RNA data
available.
b For 57 HBsAg-positive IDUs with human immunodeficiency
virus infection.
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prevalence of anti-HCV seropositivity among IDUs was
significantly higher than that in the general population [24].
These results reflect that in Taiwan, Dali (China) andTable 5 Analysis of alanine aminotransferase and hepatitis B s
nodeficiency virus.
Univariate analysis
ALT within UNL ALT more than UNL
HbsAg
Negative, n (%) 285 (85.1) 170 (82.5)
Positive, n (%) 50 (14.9) 36 (17.5)
Anti-HCV
Negative, n (%) 34 (10.1) 10 (4.9)
Positive, n (%) 301 (89.9) 196 (95.1)
Anti-HIV
Negative, n (%) 169 (50.4) 80 (38.8)
Positive, n (%) 166 (49.6) 126 (61.2)
ALTZ alanine aminotransferase; CIZ confidence interval; HBsAgZ h
immunodeficiency virus; UNL Z upper normal limit.Luxembourg, the prevalence of HBV infection among IDUs is
higher than that in the general population in Taiwan, and
HCV is significantly dominant among IDUs in Taiwan, Dali
(China), and Luxembourg [22,24]. So, for IDUs, HBV and
HCV infections are important public health issues. In addi-
tion, the prevalence of HCV infection was greater than 90%
in this study, whether HBV seropositive or seronegative,
and there was no relationship between HBC and HCV
infection in this study. These results reflected that the lack
of neutralizing antibodies for HCV and the transmission
routes and modes of HCV were similar to HBV and HIV. HCV
may be transmitted more easily than HBV and HIV among
IDUs, and we believe that for IDUs, the influence of HCV for
HBV infection is not as dominant.
In populations of the United States and Europe, HBV is
most often transmitted by sexual intercourse, followed by
injecting drug use [25,26]. In Asia and sub-Saharan Africa,
HBV is principally transmitted from mother to infant or
during early childhood [27]. In one global system survey,
the prevalence of HBsAg seropositivity was reported to be
16.7% in 2005 [7], which was higher than our result (15.3%),
though the two results were similar. In addition, approxi-
mately 10% of the HIV-infected population has concurrent
chronic hepatitis B, and HBV-HIV coinfection is more com-
mon in areas of high prevalences of both viruses. In coun-
tries in which the viruses are highly endemic [28], the rate
can be as high as 25% [29], and in areas where HBV is less
endemic (North America, Europe, and Australia), HBV and
HIV are most often acquired during adolescence or adult-
hood through sexual transmission or injecting drug use. The
prevalence of HIVeHBV coinfection in these regions is
generally lower than 10% of the HIV-infected population
[30]. Besides, in Taiwan, for IDUs with HIV infection, the
prevalence of HBsAg is 19.8% [31], and in this study, the
prevalence of HBV coinfection among IDUs with HIV infec-
tion was 18.9% (57/301). These results are higher than
those reported in a previous study (5e15%) [13]. In this
study, the prevalence of anti-HIV seropositivity was higher
among the HBsAg seropositive individuals than the HBsAg
seronegative individuals, and anti-HIV seropositivity was
related to HBsAg seropositivity. Therefore, we propose that
in Taiwan, for IDUs, especially HIV-infected individuals,
screening for HBsAg is necessary.urface antigen, anti-hepatitis C virus, and anti-human immu-
Multivariate analysis
p Odds ratio 95% CI p
0.43 1.14 0.71e1.82 0.60
0.03 2.11 1.005e4.42 0.048
0.009 1.47 1.02e2.10 0.04
epatitis B surface antigen; HCVZ hepatitis C virus; HIVZ human
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and anti-HIV antibody in this study, and the prevalence of
anti-HIV seropositivity was higher among the HBV DNA-
undetectable group. Previous studies have reported that
the natural history of HBV infection is modified by HIV
infection, which can result in higher rates of HBV and
clinically-significant disease [15,32e34]. In addition, one
study reported that persons with HIV coinfection have
higher levels of hepatitis B viremia than those with HBV
infection alone [35]. Highly active antiretroviral therapy
(HAART) can suppress HBV DNA to an undetectable level,
but in this study, only 11 participants took HAART (3TC),
and only one of these 11 participants had HBV infection, so
we believe that the number of HBV patients taking HAART
therapy was too low and almost without influence on the
results of this study. Therefore, the differences between
our results and those of a previous study [35] might be due
to the different study bases (IDUs vs. the general popula-
tion), and we suggest that the differences between our
results and those reported in a previous study [35] should
be examined in the future. In this study, anti-HCV and anti-
HIV, not HBsAg (even OR >1, but p > 0.05), were identified
as risk factors for abnormal ALT. We believe that this might
be due to the cases of HBV infection in this study being
limited, and this issue should be studied in the future.
A previous study mentioned that in individuals in Taiwan
who were born in or after 1986 and who engaged in high-
risk sexual behaviors, neonatal HBV vaccination and catch-
up vaccination provides long-term protection against HBsAg
seroconversion and HBsAg positivity [36]. In this study, the
percentage of HBsAg seropositivity was 4.0% (1/25) and
15.9% (86/541) in individuals who were born after 1985 and
before 1985, respectively, but no significant difference was
noted. However, the prevalence was higher among in-
dividuals born before 1985, and we believe that the effect
of the mass vaccination program against HBV infection was
observed among IDUs; the reason for no significant differ-
ence might be due to the number of individuals born after
1985 being too small in this study. Even the risk factors for
infection with HIV differed between this study and a pre-
vious study [36], and individuals who were born in the era of
neonatal HBV vaccination had a lower prevalence of HBsAg
seropositivity.
The CD4 cell count was higher in the HBsAg seropositive
group but lower in the HBV DNA-detectable group. The HBV
DNA level was not related to the CD4 cell count. In addition,
the CD4 cell count was also not related to anti-HBV in this
study. Therefore, we believe that the CD4 cell count is not
related to HBV among IDUs, and further advanced study to
support our result is necessary.
A limitation of this study was that the IDU participants in
this study were prisoners, so visiting and following-up these
individuals was very difficult, meaning that data collection,
such as serial changes in the disease course and therapy
given, could not be assessed completely.
In conclusion, the prevalence of HBsAg seropositivity
was found to be 15.4% among IDUs. Anti-HIV seropositivity
was related to HBsAg seropositivity. HBsAg was not found to
be a risk factor for abnormal ALT. We believe that even
though the prevalence of HBV infection among IDUs is
similar to that in the general population, HBV infection
among IDUs is still an important public health issue;therefore, from our results, we suggest that for IDUs, HBsAg
should be monitored closely, and abstinence from drug
abuse is a very important method by which to prevent HBV
infection in IDUs.
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